Biological E seeks nod for phase-3 trial of Corbevax as booster dose for Covishield, Covaxin

Currently, phase 2/3 clinical trials of the second indigenously developed Corbevax, to be administered in adults aged 18 years to 80 years, is underway and the results are likely to be declared this month.

Related Keywords

Faridabad ,Haryana ,India ,Hyderabad ,Andhra Pradesh ,Punit Goenka ,Piyush Goyal ,Union Health Ministry ,Central Drugs Standard Control Organisation ,Department Of Biotechnology ,Research Institute Translational Health Science Technology ,Invesco ,Biotechnology Industry Research Assistance Council ,Aayog Member Health Dr Vk Paul ,Expert Committee ,Drugs Controller General ,Subject Expert Committee ,Industry Research Assistance Council ,Biologicale Seeks Nod For Phase 3 Trial Of Corbevax As Booster Dose Covishield ,